Neuropsychopharmacology
- Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome2 years ago
- Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia2 years ago
- Replicability and generalizability in population psychiatric neuroimaging2 years ago
- What can neuroimaging of neuromodulation reveal about the basis of circuit therapies for psychiatry?2 years ago
- Acute sleep disruption reduces fear memories in male and female mice2 years ago
- Prevalence and correlates of irritability among U.S. adults2 years ago
- Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants2 years ago
Journal of Psychopharmacology
- Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials4 years ago
- Increasing recreational nitrous oxide use: Should we worry? A narrative review4 years ago
- Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)4 years ago
- Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study4 years ago
- Postpartum depression: A role for psychedelics?4 years ago
- Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology4 years ago
- Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial4 years ago
European Neuropsychopharmacology
- Erratum to “Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the Art. [European Neuropsychopharmacology 60 (2022) 100–116]”4 years ago
- Comment to “Requiem or resurrection: Classic monoamine oxidase inhibitors revisited”4 years ago
- A polygenic-informed approach to a predictive EEG signature empowers antidepressant treatment prediction: A proof-of-concept study4 years ago
- Associations between oxidative stress markers and patient-reported smartphone-based symptoms in patients newly diagnosed with bipolar disorder: An exploratory study4 years ago
- The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders4 years ago
- New antidepressants: New day or false dawn?4 years ago
- Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism4 years ago